Literature DB >> 17223431

Cardiac involvement in adults with m.3243A>G MELAS gene mutation.

Tom C G Vydt1, René F M de Coo, Osama I I Soliman, Folkert J Ten Cate, Robert-Jan M van Geuns, Wim B Vletter, Kees Schoonderwoerd, Bianca J C van den Bosch, Hubert J M Smeets, Marcel L Geleijnse.   

Abstract

Cardiac data in adults with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS syndrome) or asymptomatic gene carriers with the mitochondrial deoxyribonucleic acid adenine-to-guanine point mutation at nucleotide pair 3243 are scarce. Twelve subjects (mean age 35 +/- 13 years), 8 with MELAS syndrome (patients) and 4 asymptomatic gene carriers (carriers), were enrolled in the study. Each subject underwent electrocardiography, exercise testing, Holter monitoring, echocardiography, and genetic and biochemical analysis for respiratory chain enzyme activity (complex I rest activity) in skeletal muscle. On electrocardiography and Holter monitoring, none of the subjects had evidence of preexcitation, cardiac arrhythmias, or conduction abnormalities. Patients had significantly lower (42 +/- 17% from normal vs 103 +/- 14%, p <0.02) exercise tolerance. All but 1 of the patients and none of the gene carriers had ragged red fibers on muscle biopsy. The mean percentage of gene mutation in skeletal muscle tended to be higher in patients (53 +/- 19%, range 19% to 73%) compared with carriers (33 +/- 20%, range 15% to 62%). Mean complex I rest activity in patients (36 +/- 18%, range 10% to 58%) was significantly (p <0.01) lower compared with carriers (120 +/- 60%, range 72% to 205%). Left ventricular (LV) abnormalities were confined to patients with MELAS syndrome. Two patients had LV hypertrophy, 5 had LV systolic abnormalities, and 5 had LV diastolic dysfunction. Apart from 1 patient with an isolated LV diastolic abnormality, all patients with LV abnormalities had ragged red fibers. Patients with abnormal systolic LV function had a trend toward a higher percentage of mutated skeletal muscle (59.7 +/- 10.7% vs 35.8 +/- 21.3%, p <0.10) and significantly lower complex I rest activity (26.7 +/- 14.0% vs 97.8% +/- 57.9, p <0.01). In conclusion, none of the MELAS gene carriers had cardiac abnormalities, whereas most patients with the MELAS phenotype, particularly those with ragged red fibers, had LV involvement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17223431     DOI: 10.1016/j.amjcard.2006.07.089

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  Neuromuscular and systemic presentations in adults: diagnoses beyond MERRF and MELAS.

Authors:  Bruce H Cohen
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 2.  Mitochondrial sirtuins in the regulation of mitochondrial activity and metabolic adaptation.

Authors:  David B Lombard; Daniel X Tishkoff; Jianjun Bao
Journal:  Handb Exp Pharmacol       Date:  2011

3.  A Case of Myopathy, Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) Syndrome with Intracardiac Thrombus [corrected].

Authors:  Jung-Chul Joo; Myung Do Seol; Jin Won Yoon; Young Soo Lee; Dong-Keun Kim; Yong Hoon Choi; Hyo Seong Ahn; Wook Hyun Cho
Journal:  Korean Circ J       Date:  2013-03-31       Impact factor: 3.243

Review 4.  Cardiac complications in inherited mitochondrial diseases.

Authors:  Mohaddeseh Behjati; Mohammad Reza Sabri; Masood Etemadi Far; Majid Nejati
Journal:  Heart Fail Rev       Date:  2021-03       Impact factor: 4.214

Review 5.  Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management.

Authors:  Matthew G D Bates; John P Bourke; Carla Giordano; Giulia d'Amati; Douglass M Turnbull; Robert W Taylor
Journal:  Eur Heart J       Date:  2012-08-30       Impact factor: 29.983

6.  Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial disease.

Authors:  Matthew G D Bates; Jane H Newman; Djordje G Jakovljevic; Kieren G Hollingsworth; Charlotte L Alston; Pawel Zalewski; Jacek J Klawe; Andrew M Blamire; Guy A MacGowan; Bernard D Keavney; John P Bourke; Andrew Schaefer; Robert McFarland; Julia L Newton; Douglass M Turnbull; Robert W Taylor; Michael I Trenell; Gráinne S Gorman
Journal:  Int J Cardiol       Date:  2013-06-03       Impact factor: 4.164

7.  Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I.

Authors:  O I I Soliman; R G M Timmermans; A Nemes; W B Vletter; J H P Wilson; F J ten Cate; M L Geleijnse
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

8.  Defective complex I assembly due to C20orf7 mutations as a new cause of Leigh syndrome.

Authors:  M Gerards; W Sluiter; B J C van den Bosch; L E A de Wit; C M H Calis; M Frentzen; H Akbari; K Schoonderwoerd; H R Scholte; R J Jongbloed; A T M Hendrickx; I F M de Coo; H J M Smeets
Journal:  J Med Genet       Date:  2009-06-18       Impact factor: 6.318

9.  Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers.

Authors:  Matthew G D Bates; Kieren G Hollingsworth; Jane H Newman; Djordje G Jakovljevic; Andrew M Blamire; Guy A MacGowan; Bernard D Keavney; Patrick F Chinnery; Douglass M Turnbull; Robert W Taylor; Michael I Trenell; Grainne S Gorman
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-11-04       Impact factor: 6.875

10.  m.3243A>G mutation in mitochondrial DNA leads to decreased insulin sensitivity in skeletal muscle and to progressive beta-cell dysfunction.

Authors:  Markus M Lindroos; Kari Majamaa; Andrea Tura; Andrea Mari; Kari K Kalliokoski; Markku T Taittonen; Patricia Iozzo; Pirjo Nuutila
Journal:  Diabetes       Date:  2008-12-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.